A panel of biomarkers is associated with increased risk of the presence and Progression of atherosclerosis in women with systemic lupus erythematosus

Arthritis and Rheumatology

Volumn 66, Issue 1, 2014, Pages 130-139

  McMahon, Maureen ^a   Skaggs, Brian J ^a   Grossman, Jennifer M ^a   Sahakian, Lori ^a   FitzGerald, John ^a   Wong, Weng Kee ^a   Lourenco, Elaine V ^a   Ragavendra, Nagesh ^a   Charles Schoeman, Christina ^a   Gorn, Alan ^a   Karpouzas, George A ^b   Taylor, Mihaela B ^a   Watson, Karol E ^a   Weisman, Michael H ^c   Wallace, Daniel J ^c   Hahn, Bevra H ^a  

^a UCLA MEDICAL CENTER   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; APOLIPOPROTEIN A1; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HIGH SENSITIVITY C REACTIVE PROTEIN; HOMOCYSTEINE; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROINFLAMMATORY HIGH DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TNFSF12 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

ADULT; AFRICAN AMERICAN; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DYSLIPIDEMIA; ECHOGRAPHY; FAMILY HISTORY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SYSTEMIC LUPUS ERYTHEMATOSUS; AGE; BLOOD; CAROTID ARTERY DISEASE; CASE CONTROL STUDY; IMMUNOLOGY; LONGITUDINAL STUDY; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK; RISK ASSESSMENT;

ADIPONECTIN; ADULT; AGE FACTORS; APOLIPOPROTEIN A-I; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CAROTID ARTERIES; CAROTID ARTERY DISEASES; CAROTID INTIMA-MEDIA THICKNESS; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COHORT STUDIES; DIABETES COMPLICATIONS; DIABETES MELLITUS; DISEASE PROGRESSION; FEMALE; HOMOCYSTEINE; HUMANS; LEPTIN; LONGITUDINAL STUDIES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PLAQUE, ATHEROSCLEROTIC; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TUMOR NECROSIS FACTORS;

EID: 84897018442     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38204     Document Type: Article

References (50)

1. Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 2006;54:2550-7. (Pubitemid 44205016)
2. Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA Jr, Jansen-McWilliams L, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997;145:408-15. (Pubitemid 27084212)
3. Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, Du Berger R, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001;44:2331-7. (Pubitemid 32977500)
4. Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349:2399-406. (Pubitemid 37542988)
5. Schanberg LE, Sandborg C, Barnhart HX, Ardoin SP, Yow E, Evans GW, et al, for the Atherosclerosis Prevention in Pediatric Lupus Erythematosus Investigators. Use of atorvastatin in systemic lupus erythematosus in children and adolescents. Arthritis Rheum 2012;64:285-96.
6. Petri MA, Kiani AN, Post W, Christopher-Stine L, Magder LS. Lupus Atherosclerosis Prevention Study (LAPS). Ann Rheum Dis 2010;70:760-5.
7. McMahon M, Grossman J, Skaggs B, Fitz Gerald J, Sahakian L, Ragavendra N, et al. Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheum 2009;60:2428-37.
8. Navab M, Berliner JA, Watson AD, Hama SY, Territo MC, Lusis AJ, et al. The Yin and Yang of oxidation in the development of the fatty streak: a review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler Thromb Vasc Biol 1996;16:831-42. (Pubitemid 26234980)
9. Navab M, Hama SY, Hough GP, Subbanagounder G, Reddy ST, Fogelman AM. A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J Lipid Res 2001;42:1308-17. (Pubitemid 32744255)
10. McMahon M, Grossman J, Fitz Gerald J, Dahlin-Lee E, Wallace DJ, Thong BY, et al. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 2006;54:2541-9. (Pubitemid 44205015)
11. McMahon M, Skaggs BJ, Sahakian L, Grossman J, Fitz Gerald J, Ragavendra N, et al. High plasma leptin levels confer increased risk of atherosclerosis in women with systemic lupus erythematosus, and are associated with inflammatory oxidised lipids. Ann Rheum Dis 2011;70:1619-24.
12. Beltowski J. Role of leptin in blood pressure regulation and arterial hypertension. J Hypertens 2006;24:789-801. (Pubitemid 43670444)
13. Dong F, Zhang X, Ren J. Leptin regulates cardiomyocyte contractile function through endothelin-1 receptor-NADPH oxidase pathway. Hypertension 2006;47:222-9. (Pubitemid 43189767)
14. Bouloumie A, Marumo T, Lafontan M, Busse R. Leptin induces oxidative stress in human endothelial cells. FASEB J 1999;13:1231-8. (Pubitemid 29300368)
15. Sada KE, Yamasaki Y, Maruyama M, Sugiyama H, Yamamura M, Maeshima Y, et al. Altered levels of adipocytokines in association with insulin resistance in patients with systemic lupus erythematosus. J Rheumatol 2006;33:1545-52. (Pubitemid 44168825)
16. Garcia-Gonzalez A, Gonzalez-Lopez L, Valera-Gonzalez IC, Cardona-Munoz EG, Salazar-Paramo M, Gonzalez-Ortiz M, et al. Serum leptin levels in women with systemic lupus erythematosus. Rheumatol Int 2002;22:138-41. (Pubitemid 35002203)
17. Al M, Ng L, Tyrrell P, Bargman J, Bradley T, Silverman E. Adipokines as novel biomarkers in paediatric systemic lupus erythematosus. Rheumatology (Oxford) 2009;48:497-501.
18. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002;288:2015-22.
19. Von Feldt JM, Scalzi LV, Cucchiara AJ, Morthala S, Kealey C, Flagg SD, et al. Homocysteine levels and disease duration independently correlate with coronary artery calcification in patients with systemic lupus erythematosus. Arthritis Rheum 2006;54:2220-7. (Pubitemid 44051078)
20. Roman MJ, Crow MK, Lockshin MD, Devereux RB, Paget SA, Sammaritano L, et al. Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2007;56:3412-9. (Pubitemid 47585436)
21. Rua-Figueroa I, Arencibia-Mireles O, Elvira M, Erausquin C, Ojeda S, Francisco F, et al. Factors involved in the progress of preclinical atherosclerosis associated with systemic lupus erythematosus: a 2-year longitudinal study. Ann Rheum Dis 2010;69:1136-9.
22. Pan Y, Guo LL, Cai LL, Zhu XJ, Shu JL, Liu XL, et al. Homocysteine-lowering therapy does not lead to reduction in cardiovascular outcomes in chronic kidney disease patients: a meta-analysis of randomised, controlled trials. Br J Nutr 2012;108:400-7.
23. Blanco-Colio LM, Martin-Ventura JL, Munoz-Garcia B, Moreno JA, Meilhac O, Ortiz A, et al. TWEAK and Fn14: new players in the pathogenesis of atherosclerosis. Front Biosci 2007;12:3648-55.
24. Carrero JJ, Ortiz A, Qureshi AR, Martin-Ventura JL, Barany P, Heimburger O, et al. Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients. Clin J Am Soc Nephrol 2009;4:110-8.
25. Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.
26. Walitt BT, Constantinescu F, Katz JD, Weinstein A, Wang H, Hernandez RK, et al. Validation of self-report of rheumatoid arthritis and systemic lupus erythematosus: the Women's Health Initiative. J Rheumatol 2008;35:811-8. (Pubitemid 351747121)
27. Ansell BJ, Navab M, Hama S, Kamranpour N, Fonarow G, Hough G, et al. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 2003;108:2751-6. (Pubitemid 37498976)
28. Kalantar-Zadeh K, Kopple JD, Kamranpour N, Fogelman AM, Navab M. HDL-inflammatory index correlates with poor outcome in hemodialysis patients. Kidney Int 2007;72:1149-56. (Pubitemid 47609043)
29. Kim MY, Buyon JP, Petri M, Skovron ML, Shore RE. Equivalence trials in SLE research: issues to consider. Lupus 1999;8:620-6. (Pubitemid 29520527)
30. Gladman D, Urowitz M, Fortin P, Isenberg D, Goldsmith C, Gordon C, et al, Systemic Lupus International Collaborating Clinics Group. Systemic Lupus International Collaborating Clinics conference on assessment of lupus flare and quality of life measures in SLE. J Rheumatol 1996;23:1953-5. (Pubitemid 26376123)
31. Polak JF, Szklo M, Kronmal RA, Burke GL, Shea S, Zavodni AE, et al. The value of carotid artery plaque and intima-media thickness for incident cardiovascular disease: the multi-ethnic study of atherosclerosis. J Am Heart Assoc 2013;2:e000087.
32. Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955;34:1345-53.
33. Skaggs BJ, Hahn BH, Sahakian L, Grossman J, McMahon M. Dysfunctional, pro-inflammatory HDL directly upregulates monocyte PDGFRβ, chemotaxis and TNFα production. Clin Immunol 2010;137:147-56.
34. Breiman L. Random forests. Machine Learning 2001;45:5-32. (Pubitemid 32933532)
35. Melander O, Newton-Cheh C, Almgren P, Hedblad B, Berglund G, Engstrom G, et al. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA 2009;302:49-57.
36. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006;355:2631-9. (Pubitemid 44969122)
37. Folsom AR, Chambless LE, Ballantyne CM, Coresh J, Heiss G, Wu KK, et al. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the Atherosclerosis Risk in Communities Study. Arch Intern Med 2006;166:1368-73. (Pubitemid 44036348)
38. Emerging Risk Factors Collaboration. Lipid-related markers and cardiovascular disease prediction. JAMA 2012;307:2499-506.
39. Okwuosa TM, Greenland P, Ning H, Liu K, Bild DE, Burke GL, et al. Distribution of coronary artery calcium scores by Framingham 10-year risk strata in the MESA (Multi-Ethnic Study of Atherosclerosis) : potential implications for coronary risk assessment. J Am Coll Cardiol 2011;57:1838-45.
40. Zhou J, Austin RC. Contributions of hyperhomocysteinemia to atherosclerosis: causal relationship and potential mechanisms. Biofactors 2009;35:120-9.
41. Lentz SR, Sobey CG, Piegors DJ, Bhopatkar MY, Faraci FM, Malinow MR, et al. Vascular dysfunction in monkeys with dietinduced hyperhomocyst (e) inemia. J Clin Invest 1996;98:24-9. (Pubitemid 26243816)
42. Davi G, Falco A. Oxidant stress, inflammation and atherogenesis. Lupus 2005;14:760-4. (Pubitemid 41413307)
43. Vazquez E, Sethi AA, Freeman L, Zalos G, Chaudhry H, Haser E, et al. High-density lipoprotein cholesterol efflux, nitration of apolipoprotein A-I, and endothelial function in obese women. Am J Cardiol 2012;109:527-32.
44. Hahn BH, Lourencco EV, McMahon M, Skaggs B, Le E, Anderson M, et al. Pro-inflammatory high-density lipoproteins and atherosclerosis are induced in lupus-prone mice by a high-fat diet and leptin. Lupus 2010;19:913-7.
45. Schwartz N, Su L, Burkly LC, Mackay M, Aranow C, Kollaros M, et al. Urinary TWEAK and the activity of lupus nephritis. J Autoimmun 2006;27:242-50. (Pubitemid 46206104)
46. Munoz-Garcia B, Moreno JA, Lopez-Franco O, Sanz AB, Martin-Ventura JL, Blanco J, et al. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) enhances vascular and renal damage induced by hyperlipidemic diet in ApoE-knockout mice. Arterioscler Thromb Vasc Biol 2009;29:2061-8.
47. Blanco-Colio LM, Martin-Ventura JL, Munoz-Garcia B, Orbe J, Paramo JA, Michel JB, et al. Identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis. Arterioscler Thromb Vasc Biol 2007;27:916-22. (Pubitemid 46606725)
48. Chorianopoulos E, Jarr K, Steen H, Giannitsis E, Frey N, Katus HA. Soluble TWEAK is markedly upregulated in patients with ST-elevation myocardial infarction and related to an adverse short-term outcome. Atherosclerosis 2010;211:322-6.
49. Gungor O, Kircelli F, Asci G, Carrero JJ, Tatar E, Demirci MS, et al. Soluble TWEAK level: is it a marker for cardiovascular disease in long-term hemodialysis patients? J Nephrol 2013;26:136-43.
50. Manzi S, Selzer F, Sutton-Tyrrell K, Fitzgerald SG, Rairie JE, Tracy RP, et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 1999;42:51-60. (Pubitemid 29042570)